

isolating from an individual one or more pAPC selected from the group consisting of: mature pAPC, immature pAPC, and precursors to pAPC; and
exposing the isolated cells to an allergic antigen so that pAPC displaying the antigen are generated, and a pre-determined set of cytokines is expressed.

52. (Amended) The method of claim [51] 50, wherein:
the antigen-exposed pAPC are mature pAPC.

53. (Amended) The method of claim [51] 50, wherein:
the antigen-exposed pAPC are immature pAPC.

54. (Amended) The method of claim [51] 50, wherein:
the pAPC are selected from the group consisting of dendritic cells, B cells, and macrophages.

55. (Amended) The method of claim [51] 50, wherein:
the pAPC are dendritic cells.

108. (Twice Amended) The method of claim [51] 50, further comprising:
administering antigen to the subject.

109. (Amended) A method of modulating an immune system response to an antigen,
the method comprising steps of:

isolating from an individual one or more APC selected from the group consisting of: mature pAPC, immature pAPC, and precursors of pAPC;

exposing the isolated cells to an allergic antigen so that mature pAPC displaying the antigen are generated; and

contacting the antigen-exposed pAPC with T cells so that a pre-determined T-cell response is inhibited.

115. (Amended) The method of claim 109, wherein:
the step of contacting comprises contacting the antigen exposed pAPC with T cells in the presence of a Th1 inducing agent, so that the expression of one or more Th1 cytokines is induced and Th2 response is inhibited in the T cells.

129. (Amended) The method of claim 109 [125], wherein:
the step of exposing further comprises exposing the cells to a factor selected from the group consisting of cytokines and inducing agents.

160. (Amended) A method of treating allergy, the method comprising steps of:
identifying an individual who is allergic to an allergic antigen;
providing a composition of pAPC displaying the antigen; and
contacting the composition with T cells of the individual under conditions that inhibit a Th2 response to the antigen.

Cancel claims 1-49, 56-59, 62, 70-78, 99-101, 113-114, 118-121, 124, 128, 130-135, 158-159, 177-183, and 194-281.

Remarks

Claims 1-281 are pending in the Application; and claims 1-49, 56-59, 62, 70-78, 99-101, 113-114, 118-121, 124, 128, 130-135, 158-159, 177-183, and 194-281, as well as claims 50-55, 60, 63-66, 79-81, 84-91, 94-97, 102-104, and 108 which were amended in the last Response, have been withdrawn from further consideration by the Examiner, 37 CFR §1.142(b), as being drawn to non-elected inventions. Claims 61, 67-69, 82-83, 92-93, 98, 105-107, 110, 117, 127, 140-141, 151-152, 157, 176, 186-187, and 192-193 have been withdrawn as being drawn to non-elected species from Group IV. Claims 109, 111-112, 115-116, 122-123, 125-126, 129, 136-139, 142-150, 153-156, 160-175, 184-185, and 188-191 stand rejected. Claims 50, 52, 53, 54,